C07D 239/72
Quinazolines
Official title: Quinazolines; Hydrogenated quinazolines
C07D239/72 (Quinazolines) appears on 2,389 US grants and 2,505 published applications in this corpus.
Search patents in C07D- Granted patents
- 2,389
- Published applications
- 2,505
- Assignees
- 1,132
- Inventors
- 8,057
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 28 | 0 |
| 1977 | 14 | 0 |
| 1978 | 24 | 0 |
| 1979 | 19 | 0 |
| 1980 | 19 | 0 |
| 1981 | 18 | 0 |
| 1982 | 17 | 0 |
| 1983 | 15 | 0 |
| 1984 | 20 | 0 |
| 1985 | 18 | 0 |
| 1986 | 23 | 0 |
| 1987 | 28 | 0 |
| 1988 | 22 | 0 |
| 1989 | 21 | 0 |
| 1990 | 14 | 0 |
| 1991 | 11 | 0 |
| 1992 | 17 | 0 |
| 1993 | 29 | 0 |
| 1994 | 30 | 0 |
| 1995 | 31 | 0 |
| 1996 | 21 | 0 |
| 1997 | 28 | 0 |
| 1998 | 61 | 0 |
| 1999 | 52 | 0 |
| 2000 | 37 | 0 |
| 2001 | 58 | 16 |
| 2002 | 66 | 57 |
| 2003 | 49 | 79 |
| 2004 | 38 | 109 |
| 2005 | 39 | 141 |
| 2006 | 66 | 99 |
| 2007 | 58 | 108 |
| 2008 | 48 | 108 |
| 2009 | 56 | 116 |
| 2010 | 78 | 148 |
| 2011 | 82 | 106 |
| 2012 | 86 | 96 |
| 2013 | 109 | 102 |
| 2014 | 94 | 107 |
| 2015 | 104 | 111 |
| 2016 | 80 | 102 |
| 2017 | 99 | 106 |
| 2018 | 79 | 93 |
| 2019 | 93 | 102 |
| 2020 | 79 | 104 |
| 2021 | 59 | 77 |
| 2022 | 56 | 94 |
| 2023 | 45 | 111 |
| 2024 | 50 | 101 |
| 2025 | 58 | 66 |
| 2026 | 43 | 46 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C07D 239/86With hetero atoms directly attached in position 41,321
- C07D 239/95With hetero atoms directly attached in positions 2 and 4640
- C07D 239/78With hetero atoms directly attached in position 2444
- C07D 239/74With only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring307
Recent patents
- Membrane-active anti-bacterial compounds and uses thereof29 Sep 2026US 12,747,213 B2Regents of the University of Minnesota
- Sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-y1]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate monohydrate, its preparation and use22 Sep 2026US 12,741,943 B2AIC246 AG & Co. KG
- Direct aromatic carbon-oxygen and carbon-hydrogen bond functionalization via organic photoredox catalyst8 Sep 2026US 12,729,169 B2The University of North Carolina at Chapel Hill
- Quinazoline-4(3H)-one derivatives as negative allosteric modulators of metabotropic glutamate receptor 225 Aug 2026US 12,715,879 B2Vanderbilt University
- Crystalline form, and process for its production11 Aug 2026US 12,703,688 B1Alterity Therapeutics Limited
- Protein kinase inhibitors and uses thereof1 Oct 2026US 2026/0297035 A1DELiver Therapeutics, Inc.
- Precipitation process for amorphous letermovir1 Oct 2026US 2026/0297036 A1Lupin Limited
- Compound comprising n-methylpiperazine ethanol carbamate structure and use thereof1 Oct 2026US 2026/0297037 A1Korea Institute of Radiological & Medical Sciences
- Modulators of sortilin activity24 Sep 2026US 2026/0285802 A1
- Piperazinyl-Modified Quinazolinyl-Aryl Urea Derivative, And Preparation Method And Use Thereof24 Sep 2026US 2026/0285816 A1Guangxi Normal University
Most cited
By later US patents
- Alkynyl and azido-substituted 4-anilinoquinazolines379US 5,747,498 APfizer Inc. · 1998
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996
- Quinazoline derivatives217US 5,770,599 AZeneca Limited · 1998
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase198US 5,710,158 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1998